{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T05:43:02Z","timestamp":1790228582414,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,1,4]],"date-time":"2019-01-04T00:00:00Z","timestamp":1546560000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1007\/s00417-018-04223-9","type":"journal-article","created":{"date-parts":[[2019,1,4]],"date-time":"2019-01-04T16:24:36Z","timestamp":1546619076000},"page":"913-920","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Bevacizumab versus bevacizumab and macular grid photocoagulation for macular edema in eyes with non-ischemic branch retinal vein occlusion: results from a prospective randomized study"],"prefix":"10.1007","volume":"257","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0475-1093","authenticated-orcid":false,"given":"Josep","family":"Callizo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abed","family":"Atili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina Antonia","family":"Striebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Bemme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Feltgen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Hoerauf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Bertelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,4]]},"reference":[{"key":"4223_CR1","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/j.ophtha.2010.01.058","volume":"117","author":"SL Rogers","year":"2010","unstructured":"Rogers SL, McIntosh RL, Lim L et al (2010) Natural history of branch retinal vein occlusion: an evidence-based systematic review. Ophthalmology 117:1094\u20131101.e5. \n                    https:\/\/doi.org\/10.1016\/j.ophtha.2010.01.058","journal-title":"Ophthalmology"},{"key":"4223_CR2","doi-asserted-by":"publisher","unstructured":"Jaulim A, Ahmed B, Khanam T, Chatziralli IP (2013) Branch retinal vein occlusion: epidemiology, pathogenesis, risk factors, clinical features, diagnosis, and complications. An update of the literature. Retina (Philadelphia, Pa) 33:901\u2013910. \n                    https:\/\/doi.org\/10.1097\/IAE.0b013e3182870c15","DOI":"10.1097\/IAE.0b013e3182870c15"},{"key":"4223_CR3","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1097\/IAE.0000000000000843","volume":"36","author":"M Ho","year":"2016","unstructured":"Ho M, Liu DTL, Lam DSC, Jonas JB (2016) Retinal vein occlusions, from basics to the latest treatment. Retina (Philadelphia, Pa) 36:432\u2013448. \n                    https:\/\/doi.org\/10.1097\/IAE.0000000000000843","journal-title":"Retina (Philadelphia, Pa)"},{"key":"4223_CR4","doi-asserted-by":"publisher","unstructured":"Lam FC, Chia SN, Lee RMH (2015) Macular grid laser photocoagulation for branch retinal vein occlusion. Cochrane Database Syst Rev CD008732. \n                    https:\/\/doi.org\/10.1002\/14651858.CD008732.pub2","DOI":"10.1002\/14651858.CD008732.pub2"},{"key":"4223_CR5","doi-asserted-by":"crossref","unstructured":"The Branch Vein Occlusion Study Group (1984) Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol 98:271\u2013282","DOI":"10.1016\/0002-9394(84)90316-7"},{"key":"4223_CR6","doi-asserted-by":"crossref","unstructured":"Branch Vein Occlusion Study Group (1986) Argon laser scatter photocoagulation for prevention of neovascularization and vitreous hemorrhage in branch vein occlusion. A randomized clinical trial. Arch Ophthalmol 104:34\u201341","DOI":"10.1001\/archopht.1986.01050130044017"},{"key":"4223_CR7","doi-asserted-by":"publisher","first-page":"607","DOI":"10.5301\/ejo.5000085","volume":"22","author":"S Donati","year":"2012","unstructured":"Donati S, Barosi P, Bianchi M et al (2012) Combined intravitreal bevacizumab and grid laser photocoagulation for macular edema secondary to branch retinal vein occlusion. Eur J Ophthalmol 22:607\u2013614. \n                    https:\/\/doi.org\/10.5301\/ejo.5000085","journal-title":"Eur J Ophthalmol"},{"key":"4223_CR8","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1111\/j.1600-0420.2006.00850.x","volume":"85","author":"U Spandau","year":"2007","unstructured":"Spandau U, Wickenh\u00e4user A, Rensch F, Jonas J (2007) Intravitreal bevacizumab for branch retinal vein occlusion. Acta Ophthalmol Scand 85:118\u2013119. \n                    https:\/\/doi.org\/10.1111\/j.1600-0420.2006.00850.x","journal-title":"Acta Ophthalmol Scand"},{"key":"4223_CR9","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1097\/IAE.0b013e318030e77e","volume":"27","author":"MD Rabena","year":"2007","unstructured":"Rabena MD, Pieramici DJ, Castellarin AA et al (2007) Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion. Retina (Philadelphia, Pa) 27:419\u2013425. \n                    https:\/\/doi.org\/10.1097\/IAE.0b013e318030e77e","journal-title":"Retina (Philadelphia, Pa)"},{"key":"4223_CR10","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.ajo.2006.12.037","volume":"143","author":"SA Pai","year":"2007","unstructured":"Pai SA, Shetty R, Vijayan PB et al (2007) Clinical, anatomic, and electrophysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion. Am J Ophthalmol 143:601\u2013606. \n                    https:\/\/doi.org\/10.1016\/j.ajo.2006.12.037","journal-title":"Am J Ophthalmol"},{"key":"4223_CR11","doi-asserted-by":"publisher","first-page":"e78538","DOI":"10.1371\/journal.pone.0078538","volume":"8","author":"A Pielen","year":"2013","unstructured":"Pielen A, Feltgen N, Isserstedt C et al (2013) Efficacy and safety of intravitreal therapy in macular edema due to branch and central retinal vein occlusion: a systematic review. PLoS One 8:e78538. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0078538","journal-title":"PLoS One"},{"key":"4223_CR12","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1159\/000381357","volume":"234","author":"AR Berger","year":"2015","unstructured":"Berger AR, Cruess AF, Altomare F et al (2015) Optimal treatment of retinal vein occlusion: Canadian expert consensus. Ophthalmologica 234:6\u201325. \n                    https:\/\/doi.org\/10.1159\/000381357","journal-title":"Ophthalmologica"},{"key":"4223_CR13","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1016\/j.ophtha.2016.02.030","volume":"123","author":"R Tadayoni","year":"2016","unstructured":"Tadayoni R, Waldstein SM, Boscia F et al (2016) Individualized stabilization criteria-driven ranibizumab versus laser in branch retinal vein occlusion: six-month results of BRIGHTER. Ophthalmology 123:1332\u20131344. \n                    https:\/\/doi.org\/10.1016\/j.ophtha.2016.02.030","journal-title":"Ophthalmology"},{"key":"4223_CR14","doi-asserted-by":"publisher","first-page":"296","DOI":"10.4103\/0974-9233.142264","volume":"21","author":"SV Azad","year":"2014","unstructured":"Azad SV, Salman A, Mahajan D et al (2014) Comparative evaluation between ranibizumab combined with laser and bevacizumab combined with laser versus laser alone for macular oedema secondary to branch retinal vein occlusion. Middle East Afr J Ophthalmol 21:296\u2013301. \n                    https:\/\/doi.org\/10.4103\/0974-9233.142264","journal-title":"Middle East Afr J Ophthalmol"},{"key":"4223_CR15","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.ophtha.2008.12.033","volume":"116","author":"M Taban","year":"2009","unstructured":"Taban M, Sharma S, Williams DR et al (2009) Comparing retinal thickness measurements using automated fast macular thickness map versus six-radial line scans with manual measurements. Ophthalmology 116:964\u2013970. \n                    https:\/\/doi.org\/10.1016\/j.ophtha.2008.12.033","journal-title":"Ophthalmology"},{"key":"4223_CR16","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s00417-008-0916-2","volume":"247","author":"GB Jaissle","year":"2009","unstructured":"Jaissle GB, Leitritz M, Gelisken F et al (2009) One-year results after intravitreal bevacizumab therapy for macular edema secondary to branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 247:27\u201333. \n                    https:\/\/doi.org\/10.1007\/s00417-008-0916-2","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"4223_CR17","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1136\/bjophthalmol-2013-303121","volume":"98","author":"T Hikichi","year":"2014","unstructured":"Hikichi T, Higuchi M, Matsushita T et al (2014) Two-year outcomes of intravitreal bevacizumab therapy for macular oedema secondary to branch retinal vein occlusion. Br J Ophthalmol 98:195\u2013199. \n                    https:\/\/doi.org\/10.1136\/bjophthalmol-2013-303121","journal-title":"Br J Ophthalmol"},{"key":"4223_CR18","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s00417-012-2016-6","volume":"250","author":"T Yilmaz","year":"2012","unstructured":"Yilmaz T, Cordero-Coma M (2012) Use of bevacizumab for macular edema secondary to branch retinal vein occlusion: a systematic review. Graefes Arch Clin Exp Ophthalmol 250:787\u2013793. \n                    https:\/\/doi.org\/10.1007\/s00417-012-2016-6","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"4223_CR19","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.ophtha.2010.02.021","volume":"117","author":"PA Campochiaro","year":"2010","unstructured":"Campochiaro PA, Heier JS, Feiner L et al (2010) Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 117:1102\u20131112.e1. \n                    https:\/\/doi.org\/10.1016\/j.ophtha.2010.02.021","journal-title":"Ophthalmology"},{"key":"4223_CR20","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.ophtha.2015.09.035","volume":"123","author":"WL Clark","year":"2016","unstructured":"Clark WL, Boyer DS, Heier JS et al (2016) Intravitreal aflibercept for macular edema following branch retinal vein occlusion: 52-week results of the VIBRANT study. Ophthalmology 123:330\u2013336. \n                    https:\/\/doi.org\/10.1016\/j.ophtha.2015.09.035","journal-title":"Ophthalmology"},{"key":"4223_CR21","doi-asserted-by":"publisher","first-page":"434","DOI":"10.5301\/EJO.2010.6101","volume":"21","author":"A Salinas-Alam\u00e1n","year":"2011","unstructured":"Salinas-Alam\u00e1n A, Zarranz-Ventura J, Caire Gonz\u00e1lez-Jauregui JM et al (2011) Intravitreal bevacizumab associated with grid laser photocoagulation in macular edema secondary to branch retinal vein occlusion. Eur J Ophthalmol 21:434\u2013439. \n                    https:\/\/doi.org\/10.5301\/EJO.2010.6101","journal-title":"Eur J Ophthalmol"},{"key":"4223_CR22","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1089\/jop.2014.0069","volume":"31","author":"C-S Yang","year":"2015","unstructured":"Yang C-S, Liu J-H, Chung Y-C et al (2015) Combination therapy with intravitreal bevacizumab and macular grid and scatter laser photocoagulation in patients with macular edema secondary to branch retinal vein occlusion. J Ocul Pharmacol Ther 31:179\u2013185. \n                    https:\/\/doi.org\/10.1089\/jop.2014.0069","journal-title":"J Ocul Pharmacol Ther"},{"key":"4223_CR23","doi-asserted-by":"publisher","first-page":"S78","DOI":"10.1016\/j.ophtha.2016.04.056","volume":"123","author":"PA Campochiaro","year":"2016","unstructured":"Campochiaro PA, Aiello LP, Rosenfeld PJ (2016) Anti-vascular endothelial growth factor agents in the treatment of retinal disease: from bench to bedside. Ophthalmology 123:S78\u2013S88. \n                    https:\/\/doi.org\/10.1016\/j.ophtha.2016.04.056","journal-title":"Ophthalmology"},{"key":"4223_CR24","doi-asserted-by":"publisher","first-page":"761","DOI":"10.5301\/ejo.5000448","volume":"24","author":"E Farese","year":"2014","unstructured":"Farese E, Cennamo G, Velotti N et al (2014) Intravitreal bevacizumab combined with grid photocoagulation in recurrent macular edema secondary to retinal vein occlusion. Eur J Ophthalmol 24:761\u2013770. \n                    https:\/\/doi.org\/10.5301\/ejo.5000448","journal-title":"Eur J Ophthalmol"},{"key":"4223_CR25","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.1111\/aos.12488","volume":"93","author":"A Pielen","year":"2015","unstructured":"Pielen A, Mirshahi A, Feltgen N et al (2015) Ranibizumab for branch retinal vein occlusion associated macular edema study (RABAMES): six-month results of a prospective randomized clinical trial. Acta Ophthalmol 93:e29\u2013e37. \n                    https:\/\/doi.org\/10.1111\/aos.12488","journal-title":"Acta Ophthalmol"},{"key":"4223_CR26","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1016\/j.ophtha.2015.04.006","volume":"122","author":"PA Campochiaro","year":"2015","unstructured":"Campochiaro PA, Hafiz G, Mir TA et al (2015) Scatter photocoagulation does not reduce macular edema or treatment burden in patients with retinal vein occlusion: the RELATE trial. Ophthalmology 122:1426\u20131437. \n                    https:\/\/doi.org\/10.1016\/j.ophtha.2015.04.006","journal-title":"Ophthalmology"},{"key":"4223_CR27","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1016\/j.ophtha.2017.06.027","volume":"124","author":"R Tadayoni","year":"2017","unstructured":"Tadayoni R, Waldstein SM, Boscia F et al (2017) Sustained benefits of ranibizumab with or without laser in branch retinal vein occlusion: 24-month results of the BRIGHTER study. Ophthalmology 124:1778\u20131787. \n                    https:\/\/doi.org\/10.1016\/j.ophtha.2017.06.027","journal-title":"Ophthalmology"},{"key":"4223_CR28","doi-asserted-by":"publisher","first-page":"173","DOI":"10.2147\/OPTH.S37544","volume":"7","author":"N Feucht","year":"2013","unstructured":"Feucht N, Sch\u00f6nbach EM, Lanzl I et al (2013) Changes in the foveal microstructure after intravitreal bevacizumab application in patients with retinal vascular disease. Clin Ophthalmol 7:173\u2013178. \n                    https:\/\/doi.org\/10.2147\/OPTH.S37544","journal-title":"Clin Ophthalmol"},{"key":"4223_CR29","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1097\/IAE.0000000000001403","volume":"37","author":"J-W Kang","year":"2017","unstructured":"Kang J-W, Yoo R, Jo YH, Kim HC (2017) Correlation of microvascular structures on optical coherence tomography angiography with visual acuity in retinal vein occlusion. Retina (Philadelphia, Pa) 37:1700\u20131709. \n                    https:\/\/doi.org\/10.1097\/IAE.0000000000001403","journal-title":"Retina (Philadelphia, Pa)"},{"key":"4223_CR30","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1167\/iovs.13-13049","volume":"55","author":"MM Liu","year":"2014","unstructured":"Liu MM, Wolfson Y, Bressler SB et al (2014) Comparison of time- and spectral-domain optical coherence tomography in management of diabetic macular edema. Invest Ophthalmol Vis Sci 55:1370\u20131377. \n                    https:\/\/doi.org\/10.1167\/iovs.13-13049","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-018-04223-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00417-018-04223-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-018-04223-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,3]],"date-time":"2020-01-03T19:12:04Z","timestamp":1578078724000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00417-018-04223-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,4]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["4223"],"URL":"https:\/\/doi.org\/10.1007\/s00417-018-04223-9","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,4]]},"assertion":[{"value":"5 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}